Since the approval of FORZINITY by the United States' Food and Drug Administration, many of you have questions about access to the treatment.
We have answered some of the most frequent questions in the document below. We are learning alongside you, and we will continue to communicate with you as information becomes available. Please note we are not able to advise on the Expanded Access Program process or criteria used to make a decision.
If you'd like to submit a question for consideration in the next version of the FAQs, you may do so here. Due to a high volume of questions, we are not able to respond individually to queries submitted through this form.
